Journal profile · Pharmacology, Toxicology and Pharmaceutics-Drug Discovery
Current Molecular Pharmacology
ISSN 1874-4672 · eISSN 1874-4702 · KEAI PUBLISHING LTD · United Arab Emirates
Current Molecular Pharmacology: CAS Zone 4 · Biology (2025 upgraded edition); impact factor 7.11; fully open access; APC charged, amount not published; median 99 days to acceptance (17 articles, last 24 months); 40 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Current Molecular Pharmacology is published by KEAI PUBLISHING LTD and is in Zone 4 of Biology in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Ion channel regulation and function, MicroRNA in disease regulation and Neuroscience and Neuropharmacology Research, together about 18.1% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Volumes 1-17 of Current Molecular Pharmacology published by Bentham Science can be accessed here: https://www.benthamscience.com/journal/98. Current Molecular Pharmacology is a peer-reviewed international journal dedicated to publishing the latest advancements in cellular and molecular pharmacology. It emphasizes the mechanisms of action of novel drugs under development, innovative pharmacological technologies, and the application of genomics, proteomics, and metabonomics to drug action. Additionally, the journal explores how the study of drug actions at the cellular and molecular level provides insights into normal biological functions, fostering a deeper understanding of both therapeutic interventions and fundamental biological processes. This journal contains five sections:Section A (Mechanism of Action of Novel Drugs): This section focuses on understanding the mechanisms by which novel drugs under development exert their effects, covering molecular targets, pharmacodynamic and pharmacokinetic studies, structure-activity relationships (SAR), and preclinical and clinical insights into drug mechanisms.Section B (Innovative Pharmacological Technologies): This section highlights advances in pharmacological technologies and methodologies, including high-throughput screening, drug delivery systems, nanotechnology, computational pharmacology, AI-driven drug discovery, and novel experimental models for drug testing.Section C (Cell Signaling and Transduction Pathways): This section explores the analysis of cellular signaling and transduction pathways relevant to drug action, including key pathways, receptor-ligand interactions, cross-talk between pathways, and pharmacological modulation of signaling networks.Section D (Omics Applications in Pharmacology): This section focuses on the integration of genomics, proteomics, and metabonomics in understanding drug action, covering pharmacogenomics, proteomic profiling of drug responses, metabonomic studies of drug metabolism and toxicity, and multi-omics approaches to drug discovery.Section E (Drug Actions and Biological Functions): This section examines how drug actions at the cellular and molecular level illuminate normal biological functions, including drug-induced modulation of physiological processes, insights into disease mechanisms, and translational research linking molecular pharmacology to clinical outcomes.Editorial Board
From the journal's Aims & Scope
Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-Drug Discovery
Main research topics OpenAlex counts of recent articles; shares are approximate
- Ion channel regulation and functionBiochemistry, Genetics and Molecular Biology6.5%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology6%
- Neuroscience and Neuropharmacology ResearchNeuroscience5.6%
- Receptor Mechanisms and SignalingBiochemistry, Genetics and Molecular Biology5%
- Cancer, Lipids, and MetabolismBiochemistry, Genetics and Molecular Biology5%
- Peroxisome Proliferator-Activated ReceptorsBiochemistry, Genetics and Molecular Biology4.8%
- Computational Drug Discovery MethodsComputer Science4.5%
- Stress Responses and CortisolNeuroscience4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Biology Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Biology | Zone 4 |
| Minor | Biochemistry & Molecular Biology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Biology Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Biology | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Biology Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Biology | Zone 4 |
| Minor | Biochemistry & Molecular Biology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 7.11LetPub ·
- Impact factor (publisher)
- 7.2Publisher website ·
- CiteScore 2026-06
- 7.8LetPub ·
- SJR 2026-06
- 1.02LetPub ·
- SNIP 2026-06
- 0.92LetPub ·
- h-index
- 34LetPub ·
- h-index
- 60OpenAlex ·
- i10-index
- 451OpenAlex ·
- 2-year mean citedness
- 8.51OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 58.16%LetPub ·
Volume
- Articles per year
- 25LetPub ·
Articles by year OpenAlex count · 921 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 36 | 36 | 9 |
| 2025 | 40 | 28 | 265 |
| 2024 | 48 | 47 | 781 |
| 2023 | 57 | 47 | 755 |
| 2022 | 87 | 4 | 1,019 |
| 2021 | 103 | 4 | 1,443 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
99 daysMedian, submission to acceptance · P25–P75 70 days – 112 days
- Acceptance to online
- median 59 days (17 articles)
- Submission to online
- median 155 days
- Sample
- 17 articles with submission and acceptance dates (84 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessLetPub
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- ≤ 300 words
- Keywords
- ≥ 3
- Reference style
- Numbered, in order of citation
- Highlights
- Optional
- Graphical abstract
- Optional
Article types accepted3, with length limits
- letterCurrent Molecular Pharmacology publishes:Article TypeDescriptionLengthFull Length ArticleA report on new research findings or conceptual analysis that makes a s…Length not stated
- letter to the editorCurrent Molecular Pharmacology publishes:Article TypeDescriptionLengthFull Length ArticleA report on new research findings or conceptual analysis that makes a s…Length not stated
- opinionCurrent Molecular Pharmacology publishes:Article TypeDescriptionLengthFull Length ArticleA report on new research findings or conceptual analysis that makes a s…main text ≤ 12,000 words
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright Creative Commons Attribution (CC BY)
Allows users to: distribute and copy the article; create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation); include in a collective work (such as an anthology); and text or data mine the article. These uses are permitted even for commercial purposes, provided the user: gives appropriate credit to the author(s) (with a lin…
Source ↗Publisher website ·- Open access KeAi Guide for authors: Open Access
This is an open access journal: all articles will be immediately and permanently free for everyone to read and download. To provide open access, this journal has an open access fee (also known as an article publishing charge APC) which needs to be paid by the authors or on their behalf e.g. by their research funder or institution. Permitted third party (re)use is defined by the following Creative …
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors to determine suitability for publication in this journal. If your submission is deemed suitable, it will typically be sent to a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected will…
Source ↗Publisher website ·- Preprints Preprint sharing
Authors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- KEAI PUBLISHING LTD
- Country or region
- United Arab Emirates
- Language
- English
- ISSN
- 1874-4672
- Electronic ISSN
- 1874-4702
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
FAQ
Frequently asked questions about Current Molecular Pharmacology
What CAS zone is Current Molecular Pharmacology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Current Molecular Pharmacology is in Zone 4 of Biology, and in Zone 4 of the minor category Biochemistry & Molecular Biology / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 2 of Biology. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Current Molecular Pharmacology?
The latest impact factor listed by LetPub is 7.11; CiteScore 7.8, h-index 60.
How long does peer review take at Current Molecular Pharmacology?
Based on the dates recorded on 17 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 99 days (interquartile range 70–112 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Current Molecular Pharmacology?
According to the journal's author guidelines: Abstract: ≤ 300 words; Keywords: ≥ 3; Reference style: Numbered, in order of citation; Highlights: Optional; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Which databases index Current Molecular Pharmacology?
According to LetPub and DOAJ records, Current Molecular Pharmacology is indexed in SCIE and Scopus.
Is Current Molecular Pharmacology open access, and what is the APC?
Current Molecular Pharmacology is a fully open-access journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .